These mesenchymal stem cells help regulate the overactive immune response characteristic of lupus by suppressing pro-inflammatory cytokines and promoting the release of anti-inflammatory factors. Administered intravenously, WJ-MSCs can migrate to inflamed tissues, reduce systemic inflammation, and help repair damaged organs affected by the disease, such as the kidneys, skin, and joints. Their ability to modulate the immune system without triggering significant immune rejection makes them a promising, non-invasive therapeutic option for lupus patients.
